Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in …
R Biaoxue, Y Shuanying, L Wei, Z Wei… - … Medical Research and …, 2012 - Taylor & Francis
Purpose: Gefitinib is a well known therapy for non-small-cell lung cancer (NSCLC). The
purpose of this study was to review clinical reports of gefitinib as maintenance therapy after …
purpose of this study was to review clinical reports of gefitinib as maintenance therapy after …
[HTML][HTML] Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in …
H Zhao, Y Fan, S Ma, X Song, B Han, Y Cheng… - Journal of Thoracic …, 2015 - Elsevier
Background The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-
TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with …
TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with …
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
F Cappuzzo, A Morabito, N Normanno, P Bidoli… - Lung Cancer, 2016 - Elsevier
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials
BACKGROUND: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …
[HTML][HTML] Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
Survival outcomes in EGFR mutation-positive lung cancer patients treated with gefitinib until or beyond progression
FV Moiseyenko, VM Moiseyenko… - Oncology Research …, 2016 - karger.com
Background: Discontinuation of gefitinib treatment is often accompanied by a disease flare.
Some studies have demonstrated a benefit of the use of epidermal growth factor receptor …
Some studies have demonstrated a benefit of the use of epidermal growth factor receptor …
[HTML][HTML] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer chemotherapy and …, 2010 - Springer
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of …
Purpose Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …
[HTML][HTML] Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review
X Chen, Y Liu, OD Røe, Y Qian, R Guo, L Zhu, Y Yin… - PloS one, 2013 - journals.plos.org
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI),
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …
Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)
FR Hirsch, LV Sequist, I Gore, M Mooradian, G Simon… - Cancer, 2018 - Wiley Online Library
BACKGROUND This is the first report of long‐term (> 10 years) safety, tolerability, and
survival data on patients with non–small cell lung cancer (NSCLC) who received treatment …
survival data on patients with non–small cell lung cancer (NSCLC) who received treatment …